Drug intelligence / Profile preview

epinephrine

Development stage
Approved
Lead developer
Sanofi
Modality
Small Molecules, Recombinant Proteins and Enzymes
Administration
Intramuscular, Intravenous, Subcutaneous, Inhalation, Topical, Intraosseous, Endotracheal, Intracardiac
01

Overview

Epinephrine is a hormone and neurotransmitter that acts as a nonselective agonist of alpha- and beta-adrenergic receptors. It is used as a medication to treat life-threatening allergic reactions (anaphylaxis), cardiac arrest, asthma exacerbations when other treatments are ineffective, croup (inhaled form), superficial bleeding, and low blood pressure due to septic shock. Epinephrine works by stimulating alpha-adrenergic receptors to cause vasoconstriction and reduce vascular permeability during anaphylaxis; it also stimulates beta-adrenergic receptors leading to bronchodilation (airway smooth muscle relaxation), increased heart rate and contractility (beta-1 effects), increased glycogenolysis in the liver and muscle, lipolysis in adipose tissue, mydriasis (pupil dilation), inhibition of insulin secretion by the pancreas (alpha effect), glucagon release from the pancreas (beta effect), ACTH secretion from the pituitary gland (beta effect) and overall increases in blood glucose and fatty acids for energy production. Epinephrine is produced synthetically for medical use; it was first isolated by Jōkichi Takamine in 1901[2][5][7][8].

Brand names
AdrenalinAuvi-QEpiPenSymjepi
Other names
adrenalineadrenalin
02

Targets

ADRA1A (α1A)ADRA2A (α2A)ADRB1 (β1)ADRB2 (β2)ADRA1 (Alpha-1 adrenergic receptor family)

Beyond the preview

Go deeper on epinephrine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on epinephrine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call